Sunovion Pharmaceuticals Inc.

Enanta Pharmaceuticals, Inc.

Entasis Therapeutics, Inc.

Frank Wu

Kerry Leigh Spear

Michele L R Heffernan

Larry Wendell Hardy

Lakshmi D Saraswat

Yat Sun Or

Zhe Wang

Zhenwei Miao

Ying Sun

Datong Tang

Guoyou Xu

Suanne Nakajima

Qun Kevin Fang

Seth C Hopkins

Ruben Alberto Tommasi

Paul T Grover

Una Campbell

Jeroen Cunera Verheijen

Milan Chytil

Thomas Francois Durand-Reville

Xiaoyun Wu

Janelle Comita-Prevoir

Jing Zhang

Jan Romero

John O'Donnell

Lise Gauthier

Gregory S Basarab

Bill Moss

The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts are useful in combination with beta-lactam antibiotics, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of R, R, R, R, Rand Rare described herein. 

Beta-lactamase inhibitor compounds

Compounds that modulate GluR5 activity and methods of using the same are disclosed.

Metabotrophic glutamate receptor 5 modulators and methods use thereof

Metabotrophic glutamate receptor 5 modulators and methods of use thereof

Provided herein are compounds of formula (I): and pharmaceutical compositions thereof, useful for the treatment of disorders mediated by metabotropic glutamate receptor 5.

Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof

Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

Imidazo[1,2-a]pyridines are disclosed. Compounds of the invention are useful therapeutic agents and their inclusion in pharmaceutical formulations and use in methods of treatment are disclosed. Many of the compounds disclosed herein may be represented by the following generic formula: 

Imidazo[1,2-a]pyridine compounds

The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: 

Macrocyclic hepatitis C serine protease inhibitors

The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:  wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Growing community of inventors

Shrewsbury, MA, United States of America

Frank Wu